New combo aims to wipe out lingering leukemia before transplant

NCT ID NCT06773208

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether two drugs, azacitidine and venetoclax, can eliminate or reduce measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who have completed standard chemotherapy and are scheduled for a donor stem cell transplant. The goal is to lower the chance of the cancer returning after transplant. About 30 participants will receive the drugs for up to 28 days per cycle, and researchers will check bone marrow samples for MRD clearance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine and venetoclax
What this could lead to: If successful, this approach could help more AML patients achieve a cancer-free state before transplant, potentially lowering relapse risk.
What could go wrong: This is a small, early-phase study (30 people) and may not work for everyone. Side effects from the drugs or transplant complications remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.